Precision BioSciences, Inc. Common Stock (DTIL) Stock Price
DTILStock
$5.77−13.10%52W
Market Cap$159.26M
P/E19.04x
PEG Ratio—
Div yield—
Beta1.44
DTIL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-30.10%
Price vs S&P 500 (4W)-9.91%
VGM Score60.56
P/E Ratio (Annual)19.04x
DTIL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.69 | -$1.26 | -81.73%(-$0.57) | |
| Q1 2026 | -$0.81 | -$0.75 | +7.41%(+$0.06) | |
| Q4 2025 | -$0.64 | $1.01 | +256.36%(+$1.65) | |
| Q3 2025 | -$2.21 | -$1.84 | +16.74%(+$0.37) | |
| Q2 2025 | -$2.21 | -$2.13 | +3.40%(+$0.08) |
DTIL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.30
4.36
4.36
4.36
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
DTILPrecision BioSciences, Inc. Common Stock | C | A | C | 3.5x | 3473.0% | — | — | $5.77 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
About Precision BioSciences, Inc. Common Stock
Precision BioSciences develops genome editing therapeutics based on its proprietary ARCUS platform. The platform's compact size enables efficient delivery to a wider range of cells and tissues using both viral and non-viral methods, potentially providing competitive advantages. The company applies ARCUS to create product candidates for human disease treatment and agricultural applications.